Integrated, multidisciplinary care for hand eczema: design of a randomized controlled trial and cost-effectiveness study

van Gils, Robin F.; van der Valk, Pieter G. M.; Bruynzeel, Derk; Coenraads, Pieter J.; Boot, Cécile R. L.; van Mechelen, Willem; Anema, Johannes R.
January 2009
BMC Public Health;2009, Vol. 9 Issue 1, p438
Academic Journal
Background: The individual and societal burden of hand eczema is high. Literature indicates that moderate to severe hand eczema is a disease with a poor prognosis. Many patients are hampered in their daily activities, including work. High costs are related to high medical consumption, productivity loss and sick leave. Usual care is suboptimal, due to a lack of optimal instruction and coordination of care, and communication with the general practitioner/occupational physician and people involved at the workplace. Therefore, an integrated, multidisciplinary intervention involving a dermatologist, a care manager, a specialized nurse and a clinical occupational physician was developed. This paper describes the design of a study to investigate the effectiveness and cost-effectiveness of integrated care for hand eczema by a multidisciplinary team, coordinated by a care manager, consisting of instruction on avoiding relevant contact factors, both in the occupational and in the private environment, optimal skin care and treatment, compared to usual, dermatologist-led care. Methods: The study is a multicentre, randomized, controlled trial with an economic evaluation alongside. The study population consists of patients with chronic, moderate to severe hand eczema, who visit an outpatient clinic of one of the participating 5 (three university and two general) hospitals. Integrated, multidisciplinary care, coordinated by a care manager, including allegro-dermatological evaluation by a dermatologist, occupational intervention by a clinical occupational physician, and counselling by a specialized nurse on optimizing topical treatment and skin care will be compared with usual care by a dermatologist. The primary outcome measure is the cumulative difference in reduction of the clinical severity score HECSI between the groups. Secondary outcome measures are the patient's global assessment, specific quality of life with regard to the hands, generic quality of life, sick leave and patient satisfaction. An economic evaluation will be conducted alongside the RCT. Direct and indirect costs will be measured. Outcome measures will be assessed at baseline and after 4, 12, 26 and 52 weeks. All statistical analyses will be performed on the intention-to-treat principle. In addition, per protocol analyses will be carried out. Discussion: To improve societal participation of patients with moderate to severe hand eczema, an integrated care intervention was developed involving both person-related and environmental factors. Such integrated care is expected to improve the patients' clinical signs, quality of life and to reduce sick leave and medical costs. Results will become available in 2011.


Related Articles

  • A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis. Schuetz, C. Andy; Alperin, Peter; Guda, Swathi; van Herick, Andrew; Cariou, Bertrand; Eddy, David; Gumprecht, Janusz; Nicolucci, Antonio; Schwarz, Peter; Wareham, Nick J.; Witte, Daniel R.; Smith, Ulf // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Background: No clinical trials have assessed the effects or cost-effectiveness of health check strategies to detect and manage vascular disease. We used a mathematical model to estimate the cost-effectiveness of several health check strategies in six European countries. Methods: We used...

  • Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Soini, E. J. O.; Martikainen, J. A.; Nousiainen, T. // Annals of Oncology;May2011, Vol. 22 Issue 5, p1189 

    Background: Rituximab induction together with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and rituximab maintenance (RCHOP-R) resulted to significant progression-free survival (PFS) benefit in comparison to RCHOP in the EORTC20981 trial of relapsed/refractory follicular...

  • On the probability of cost-effectiveness using data from randomized clinical trials. Willan, Andrew R. // BMC Medical Research Methodology;2001, Vol. 1, p8 

    Background: Acceptability curves have been proposed for quantifying the probability that a treatment under investigation in a clinical trial is cost-effective. Various definitions and estimation methods have been proposed. Loosely speaking, all the definitions, Bayesian or otherwise, relate to...

  • Dementia case management effectiveness on health care costs and resource utilization: a systematic review of randomized controlled trials. PIMOUGUET, C.; LAVAUD, T.; DARTIGUES, J. F.; HELMER, C. // Journal of Nutrition, Health & Aging;Aug2010, Vol. 14 Issue 8, p669 

    The growing number of dementia patients leads to both policy, economic and health organization constraints. Many healthcare systems have developed case management programs in order to optimize dementia patients and caregivers care and services delivery. Nevertheless, to what extend case...

  • The pathway to physician reimbursement for cardiac implantable electronic devices (CIEDs): a history and brief synopsis. Roka, Attila; Schoenfeld, Mark // Journal of Interventional Cardiac Electrophysiology;Mar2013, Vol. 36 Issue 2, p137 

    Cardiac implantable electronic devices (CIEDs), despite their proven effectiveness in large clinical trials for a wide range of patients with arrhythmia and heart failure, are frequent targets for criticism regarding cost-efficiency and alleged overuse. Newer indications, such as sinus node...

  • Lifetime health effects and medical costs of integrated stroke services - a non-randomized controlled cluster-trial based life table approach. Baeten, Stefan A.; van Exel, N Job A.; Dirks, Maaike; Koopmanschap, Marc A.; Dippel, Diederik W. J.; Niessen, Louis W. // Cost Effectiveness & Resource Allocation;2010, Vol. 8, p21 

    Background: Economic evaluation of stroke services indicates that such services may lead to improved quality of life at affordable cost. The present study assesses lifetime health impact and cost consequences of stroke in an integrated service setting. Methods: The EDISSE study is a prospective...

  • Rotavirus Vaccine RIX4414 (Rotarixâ„¢). Plosker, Greg L. // PharmacoEconomics;2011, Vol. 29 Issue 5, p439 

    The most common cause of severe diarrhoea in infants and young children is rotavirus gastroenteritis (RVGE), which is associated with significant morbidity, healthcare resource use and direct and indirect costs in industrialized nations. The monovalent rotavirus vaccine RIX4414 (Rotarix_) is...

  • The costs of clinical trials. Fletcher, Robert H.; Fletcher, R H // JAMA: Journal of the American Medical Association;10/6/89, Vol. 262 Issue 13, p1842 

    Editorial. Focuses on the cost-effectiveness of clinical trials. Definition of fixed costs and effectiveness; Reasons why policymakers do not clamor for more spending on research; View that clinical trials are a bad investment at any price; Importance of value judgments on how to spend health...

  • Cost-effectiveness of monitoring glaucoma patients in shared care: an economic evaluation alongside a randomized controlled trial. Holtzer-Goor, Kim M.; van Sprundel, Esther; Lemij, Hans G.; Plochg, Thomas; Klazinga, Niek S.; Koopmanschap, Marc A. // BMC Health Services Research;2010, Vol. 10, p312 

    Background: Population aging increases the number of glaucoma patients which leads to higher workloads of glaucoma specialists. If stable glaucoma patients were monitored by optometrists and ophthalmic technicians in a glaucoma follow-up unit (GFU) rather than by glaucoma specialists, the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics